Tongling Jieya Biologic Technology Co., Ltd. (SHE:301108)

SHE:301108 Revenue

Tongling Jieya Biologic Technology had revenue of 192.21M CNY in the quarter ending March 31, 2026, with 55.45% growth. This brings the company's revenue in the last twelve months to 840.58M, up 55.24% year-over-year. In the year 2025, Tongling Jieya Biologic Technology had annual revenue of 772.01M with 41.02% growth.

• Revenue (ttm): 840.58M
• Revenue Growth: +55.24%
• P/S Ratio: 3.65
• Revenue / Employee: 1.33M
• Employees: 634
• Market Cap: 3.07B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	772.01M	224.56M	41.02%
Dec 31, 2024	547.45M	-75.14M	-12.07%
Dec 31, 2023	622.59M	-43.98M	-6.60%
Jan 1, 2023	666.56M	-317.89M	-32.29%
Jan 1, 2022	984.45M	241.44M	32.49%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

May 1, 2026

Data Sources Report a data error